Intratio
Loading...
Skip to main content
Stock comparison · Signal date 2026-11-06

CTNM vs CYDY: stock comparison and AI forecast

Contineum Therapeutics, Inc. (CTNM) and Cytodyn Inc. (CYDY) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market

Share
Nasdaq · Pharmaceutical Preparations

CTNM Contineum Therapeutics, Inc.

Market Cap
$331M
P/E Ratio
–
Size
small-cap
AI Forecast
Full analysis →
OTC · Pharmaceutical Preparations

CYDY Cytodyn Inc.

Market Cap
$332M
P/E Ratio
–
Size
small-cap
AI Forecast
Full analysis →
Model output

Which one does the AI model favor?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

CTNM · CYDY

Key facts

  • CTNM and CYDY have similar market capitalizations ($331M and $332M).
  • Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals

Fundamentals side by side

Trailing twelve months.

Valuation & Market

MetricCTNMCYDY
Market Cap$331M$332M
EPS$-2.66$-0.04
FCF/Share$-1.39–

Profitability & Margins

MetricCTNMCYDY
ROA–-272.5%
ROIC–128.9%
Tax Rate–0.0%

Financial Health

MetricCTNMCYDY
Current Ratio31.11x0.38x
Interest Coverage–-315.1x
Working Capital$242M-$31M

Cash Flow

MetricCTNMCYDY
Operating Cash Flow-$52M-$20M
Free Cash Flow-$52M–
Capital Spending-$360K–

Income Statement

MetricCTNMCYDY
Operating Income-$72M-$40M
Net Income–-$52M
R&D Expense$53M–

Dividend & Shareholder Information

MetricCTNMCYDY
Shares Outstanding38M1470M
FAQ

CTNM vs CYDY: stock comparison and AI forecast

Which is bigger, CTNM or CYDY?

CTNM and CYDY have similar market capitalizations ($331M and $332M).

Which one does Intratio's AI model rank higher, CTNM or CYDY?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

Compare

More comparisons

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.